These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 10942856)
41. Placebo effects on human mu-opioid activity during pain. Wager TD; Scott DJ; Zubieta JK Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11056-61. PubMed ID: 17578917 [TBL] [Abstract][Full Text] [Related]
42. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Zubieta JK; Dannals RF; Frost JJ Am J Psychiatry; 1999 Jun; 156(6):842-8. PubMed ID: 10360121 [TBL] [Abstract][Full Text] [Related]
44. Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET). Bencherif B; Fuchs PN; Sheth R; Dannals RF; Campbell JN; Frost JJ Pain; 2002 Oct; 99(3):589-598. PubMed ID: 12406535 [TBL] [Abstract][Full Text] [Related]
45. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Correia CJ; Walsh SL; Bigelow GE; Strain EC Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637 [TBL] [Abstract][Full Text] [Related]
46. Cross-tolerance and mu agonist efficacy in pigeons treated with LAAM or buprenorphine. Galici R; McMahon LR; France CP Pharmacol Biochem Behav; 2005 Jul; 81(3):626-34. PubMed ID: 15946731 [TBL] [Abstract][Full Text] [Related]
47. Regional brain [(11)C]carfentanil binding following tobacco smoking. Domino EF; Hirasawa-Fujita M; Ni L; Guthrie SK; Zubieta JK Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jun; 59():100-104. PubMed ID: 25598501 [TBL] [Abstract][Full Text] [Related]
48. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Lester PA; Traynor JR Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205 [TBL] [Abstract][Full Text] [Related]
49. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. Collins ED; Kleber HD; Whittington RA; Heitler NE JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380 [TBL] [Abstract][Full Text] [Related]
50. Buprenorphine-elicited alteration of adenylate cyclase activity in human embryonic kidney 293 cells coexpressing κ-, μ-opioid and nociceptin receptors. Wang PC; Ho IK; Lee CW J Cell Mol Med; 2015 Nov; 19(11):2587-96. PubMed ID: 26153065 [TBL] [Abstract][Full Text] [Related]
51. Acute and chronic administration of clorazepate modifies the cell surface regulation of mu opioid receptors induced by buprenorphine in specific regions of the rat brain. Debruyne D; Quentin T; Poisnel G; Lelong-Boulouard V; Barré L; Coquerel A Brain Res; 2005 Aug; 1052(2):222-31. PubMed ID: 16023087 [TBL] [Abstract][Full Text] [Related]
52. Dosimetry of 11C-carfentanil, a micro-opioid receptor imaging agent. Newberg AB; Ray R; Scheuermann J; Wintering N; Saffer J; Schmitz A; Freifelder R; Karp J; Lerman C; Divgi C Nucl Med Commun; 2009 Apr; 30(4):314-8. PubMed ID: 19242386 [TBL] [Abstract][Full Text] [Related]
53. Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group. Traynor JR; Guo L; Coop A; Lewis JW; Woods JH J Pharmacol Exp Ther; 1999 Dec; 291(3):1093-9. PubMed ID: 10565829 [TBL] [Abstract][Full Text] [Related]
54. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder. Becker WC; Ganoczy D; Fiellin DA; Bohnert AS J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475 [TBL] [Abstract][Full Text] [Related]